Company News

December 4, 2024Landing Med has been honored by Forbes China as a "2024 Top Innovative Comprehensive Healthcare Company", a prestigious recognition of its transformative contributions to the...

Seoul, South Korea – October 2-4, 2024Landing Med’s Chief Technology Officer (CTO), Dr. Pang Baochuan, was invited to speak at the inaugural Asia Society of Digital Pathology Congress in Seoul, Sout...

Florence, Italy – Landing Med highlighted its groundbreaking technologies at the 2024 European Congress of Pathology (ECP) in Florence, Italy, from September 7-11, showcasing advancements in digital ...

Lusaka, Zambia – July 16-19, 2024Landing Med, a trailblazer in health technology, has been recognized as the only Asian company invited to participate in the prestigious Ending Preventable Maternal M...

Vilnius, Lithuania – Landing Med’s Founder and Chairwoman, Dr. Xiaorong Sun, was honored to be invited to speak at the prestigious European Congress of Digital and Spatial Pathology (ECDP) in Vilniu...

Landing Med, a Chinese medtech company focused on early cancer detection, has achieved a significant milestone by completing over 10 million cervical cancer screenings using artificial intelligence (AI). Established by Dr. Xiaorong Sun, the company has been integrating automation, digital, AI, and cloud computing technologies into Pap smear testing across China since 2017.

ISLAMABAD: A hospital of federal capital has joined hands with Landing Med, medical technology company, based in Wuhan China, to make use of the artificial intelligence (AI) in advancing cervical cancer screening.

Islamabad:In a landmark move towards improving cancer care, Dr. Akbar Niazi Teaching Hospital (ANTH) in Islamabad, Pakistan, has joined forces with Landing Med, medical technology company based in Wuhan, China, to make use of the Artificial Intelligence (AI) in advancing Cervical Cancer screening, says a press release.